Alam Ozair, Al-Keridis Lamya Ahmed, Khan Jalaluddin, Naaz Sameena, Alam Afshar, Ashraf Syed Amir, Alshammari Nawaf, Adnan Mohd, Beg Md Amjad
Department of Computer Science & Engineering, School of Engineering Sciences and Technology (SEST), Jamia Hamdard University, New Delhi 110062, India.
Medicinal Chemistry & Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi 110062, India.
J Funct Biomater. 2023 Feb 25;14(3):126. doi: 10.3390/jfb14030126.
Despite the existence of modern antidiabetic medications, diabetes still affects millions of individuals worldwide, with a high death and disability rate. There has been a concerted search for alternative natural medicinal agents; luteolin (LUT), a polyphenolic molecule, might be a good choice, both because of its efficacy and because of it having fewer side effects, compared to conventional medicines. This study aims to explore the antidiabetic potential of LUT in diabetic rats, induced by streptozotocin (STZ; 50 mg/kg b.w.), intraperitoneally. The level of blood glucose, oral glucose tolerance test (OGTT), body weight, glycated hemoglobin A1c (HbA1c), lipidemic status, antioxidant enzymes, and cytokines were assessed. Also, its action mechanism was explored through molecular docking and molecular dynamics simulations. Oral supplementation of LUT for 21 days resulted in a significant decrease in the blood glucose, oxidative stress, and proinflammatory cytokine levels, and modulated the hyperlipidemia profile. LUT also ameliorated the tested biomarkers of liver and kidney function. In addition, LUT markedly reversed the damage to the pancreas, liver, and kidney cells. Moreover, molecular docking and molecular dynamics simulations revealed excellent antidiabetic behavior of LUT. In conclusion, the current investigation revealed that LUT possesses antidiabetic activity, through the reversing of hyperlipidemia, oxidative stress, and proinflammatory status in diabetic groups. Therefore, LUT might be a good remedy for the management or treatment of diabetes.
尽管存在现代抗糖尿病药物，但糖尿病仍影响着全球数百万人，死亡率和致残率很高。人们一直在协同寻找替代的天然药物；木犀草素（LUT）是一种多酚类分子，可能是一个不错的选择，这不仅是因为它的疗效，还因为与传统药物相比，它的副作用更少。本研究旨在探讨腹腔注射链脲佐菌素（STZ；50 mg/kg体重）诱导的糖尿病大鼠中LUT的抗糖尿病潜力。评估了血糖水平、口服葡萄糖耐量试验（OGTT）、体重、糖化血红蛋白A1c（HbA1c）、血脂状况、抗氧化酶和细胞因子。此外，还通过分子对接和分子动力学模拟探索了其作用机制。口服LUT 21天可显著降低血糖、氧化应激和促炎细胞因子水平，并调节高脂血症。LUT还改善了所检测的肝肾功能生物标志物。此外，LUT明显逆转了胰腺、肝脏和肾脏细胞的损伤。此外，分子对接和分子动力学模拟显示LUT具有出色的抗糖尿病行为。总之，目前的研究表明，LUT通过逆转糖尿病组的高脂血症、氧化应激和促炎状态而具有抗糖尿病活性。因此，LUT可能是管理或治疗糖尿病的良好药物。
